Equities
Health CareMedical Equipment and Services
  • Price (USD)334.85
  • Today's Change0.00 / 0.00%
  • Shares traded3.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Oct 03 2024 21:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Bio Rad Laboratories Inc had revenues fall -4.67% from 2.80bn to 2.67bn, though the company grew net income from a loss of 3.63bn to a smaller loss of 637.32m.
Gross margin54.43%
Net profit margin-30.18%
Operating margin11.86%
Return on assets-6.92%
Return on equity-9.79%
Return on investment-7.26%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Bio Rad Laboratories Inc fell by 30.18m. However, the company earned 374.94m from its operations for a Cash Flow Margin of 14.04%. In addition the company generated 20.21m cash from investing, though they paid out 425.65m more in financing than they received.
Cash flow per share-22.13
Price/Cash flow per share--
Book value per share267.46
Tangible book value per share241.66
More ▼

Balance sheet in USDView more

Bio Rad Laboratories Inc has a Debt to Total Capital ratio of 13.83%, a lower figure than the previous year's 14.24%.
Current ratio6.14
Quick ratio4.52
Total debt/total equity0.1604
Total debt/total capital0.1383
More ▼

Growth rates in USD

SmartText is unavailable
EPS growth(5 years)--
EPS (TTM) vs
TTM 1 year ago
-391.52
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.